All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-12-18T12:17:49.000Z

Joshua Zeidner | ASH 2018 | Biomarker-guided phase II study in MCL-1 dependent R/R AML patients

Dec 18, 2018
Share:

Bookmark this article

At the 2018 American Society of Hematology meeting, Joshua Zeidner from the University of North Carolina, Chapel Hill, US, talks about the results from the stage 1 portion of the Zella 201 trial in which the efficacy and safety of alvocidib, in combination with cytarabine and mitoxantrone was evaluated in MCL-1 dependent relapsed or relapsed acute myeloid leukemia (AML) patients.

Alvocidib given before cytarabine and mitoxantrone in MCL-1-dependent AML has clinical activity, particularly in those refractory to frontline therapy.

Biomarker-guided phase II study in MCL-1 dependent R/R AML patients

More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox